Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $41.7 million.

  • Stoke Therapeutics' Total Current Liabilities fell 1632.01% to $41.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.7 million, marking a year-over-year decrease of 1632.01%. This contributed to the annual value of $40.1 million for FY2024, which is 2997.18% up from last year.
  • Stoke Therapeutics' Total Current Liabilities amounted to $41.7 million in Q3 2025, which was down 1632.01% from $38.7 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Total Current Liabilities ranged from a high of $49.9 million in Q3 2024 and a low of $21.8 million during Q2 2023
  • Its 4-year average for Total Current Liabilities is $34.3 million, with a median of $31.5 million in 2023.
  • In the last 5 years, Stoke Therapeutics' Total Current Liabilities crashed by 2102.07% in 2023 and then skyrocketed by 10376.43% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Total Current Liabilities (Quarter) stood at $31.4 million in 2022, then decreased by 1.83% to $30.8 million in 2023, then grew by 29.97% to $40.1 million in 2024, then increased by 4.17% to $41.7 million in 2025.
  • Its Total Current Liabilities stands at $41.7 million for Q3 2025, versus $38.7 million for Q2 2025 and $44.7 million for Q1 2025.